Cereno Scientific expands patent protection for drug candidate CS1 through its second patent family
Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS1’s second patent family has obtained patents in Israel and in Malaysia, respectively. This strengthens and broadens the intellectual property rights (IPR) for Cereno’s Phase II drug candidate CS1, which is being developed for the treatment of rare disease pulmonary arterial hypertension (PAH).
“The development of our lead drug candidate CS1 is currently progressing in a Phase II study with active patient recruitment across sites in the US. I am pleased to, in parallel, have news related to CS1’s growing patent portfolio as it is an important aspect of preparing the future commercial positioning, together with a strong clinical data set,” said Sten R. Sörensen, CEO at Cereno.
CS1’s second patent family is titled “Valproic Acid for the Treatment or Prevention of Pathological Conditions Associated With Excess Fibrin Deposition and/or Thrombus Formation” and has been assigned the patent number 251142 in Israel and patent number MY-192055-A in Malaysia. The patents will be valid through 2035, with the possibility of patent extension of up to five years. The second patent family has previously been granted in Australia, Canada, Europe, Japan, Mexico, Russia, and the US.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.